TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+9.85%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.6B
AUM Growth
+$216M
(+9.1%)
Cap. Flow
+$20.7M
Cap. Flow
% of AUM
0.8%
Top 10 Holdings %
Top 10 Hldgs %
41.87%
Holding
156
New
13
Increased
21
Reduced
24
Closed
10
Top Buys
| 1 |
Merck
MRK
|
$28M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$21.3M |
| 3 |
Abbott
ABT
|
$18M |
| 4 |
Eli Lilly
LLY
|
$17M |
| 5 |
CVS Health
CVS
|
$16.7M |
Top Sells
| 1 |
Illumina
ILMN
|
$22.7M |
| 2 |
HCA Healthcare
HCA
|
$18.1M |
| 3 |
SPDR S&P Biotech ETF
XBI
|
$15.9M |
| 4 |
MDVN
MEDIVATION, INC.
MDVN
|
$15.5M |
| 5 |
STJ
St Jude Medical
STJ
|
$12.4M |
Sector Composition
| 1 | Healthcare | 91.79% |
| 2 | Real Estate | 2.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Cardinal Health
CAH
$36B
| $11.8M | 0.46% |
+152,500
| New | +$11.8M |
|
52
Sanofi
SNY
$122B
| $11.6M | 0.45% |
305,000
| – | – |
|
53
Sabra Healthcare REIT
SBRA
$4.56B
| $11.5M | 0.44% |
456,190
| – | – |
|
|
DOC
54
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $11.4M | 0.44% |
530,672
| – | – |
|
55
Becton Dickinson
BDX
$54.3B
| $11.3M | 0.44% |
+64,655
| New | +$11.3M |
|
56
Cigna
CI
$80.2B
| $11.3M | 0.43% |
+86,400
| New | +$11.3M |
|
57
United Therapeutics
UTHR
$17.7B
| $11M | 0.42% |
93,100
| – | – |
|
58
Ventas
VTR
$30.7B
| $10.8M | 0.41% |
152,491
| – | – |
|
59
DaVita
DVA
$9.72B
| $10.6M | 0.41% |
+161,100
| New | +$10.6M |
|
|
PRTK
60
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $9.92M | 0.38% |
762,581
| – | – |
|
|
ELGX
61
DELISTED
Endologix Inc
ELGX
| $9.9M | 0.38% |
77,350
+22,250
| +40% | +$2.85M |
|
62
Natera
NTRA
$23B
| $9.8M | 0.38% |
882,358
| – | – |
|
63
Charles River Laboratories
CRL
$7.99B
| $9.58M | 0.37% |
+115,000
| New | +$9.58M |
|
64
Galapagos
GLPG
$2.06B
| $9.55M | 0.37% |
147,738
| – | – |
|
65
Ardelyx
ARDX
$1.57B
| $9.16M | 0.35% |
707,636
-681,734
| -49% | -$8.82M |
|
|
FOMX
66
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $8.95M | 0.34% |
966,065
| – | – |
|
|
AVDL
67
Avadel Pharmaceuticals
AVDL
$1.45B
| $7.74M | 0.3% |
624,288
| – | – |
|
|
PVLA
68
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $7.59M | 0.29% |
51,824
+3,722
| +8% | +$545K |
|
|
CLLS
69
Cellectis
CLLS
$260M
| $7.47M | 0.29% |
310,250
| – | – |
|
70
Travere Therapeutics
TVTX
$1.75B
| $7.38M | 0.28% |
329,949
| – | – |
|
|
71
HCA Healthcare
HCA
$95.4B
| $7.24M | 0.28% |
95,684
-239,314
| -71% | -$18.1M |
|
72
Exelixis
EXEL
$9.95B
| $7.06M | 0.27% |
551,647
-853,773
| -61% | -$10.9M |
|
|
ARIA
73
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $6.87M | 0.26% |
502,000
| – | – |
|
|
SAGE
74
DELISTED
Sage Therapeutics
SAGE
| $6.76M | 0.26% |
146,800
| – | – |
|
75
Ultragenyx Pharmaceutical
RARE
$3.04B
| $6.27M | 0.24% |
88,400
| – | – |
|